You’ve been paying more for prescription drugs — and it’s not just Mylan’s EpiPen.

Prices for prescription drugs increased 6.3% over the last 12 months, the highest year-long prescription drug price increase in over a year and a half, government consumer price index data shows.

Read more on the CPI report.

Data from the CPI, which examines changes in what consumers are paying for day-to-day goods and services, lends support to the idea that broad changes in health care are having repercussions for consumers alongside health insurers and other players.

Drug price increases have caught the scrutiny of the public and lawmakers over the last year, most recently over increases in the price of Mylan’s MYL, +0.27% EpiPen allergic reaction treatment.

Drug prices are indeed rising, and have been for many years. But the phenomenon is exacerbated by another health care trend, the rise of high deductible health insurance plans, which shift more of health care costs to consumers.

See: Medical costs jump in August by largest amount in 32 years, CPI shows

Though other factors, such as new terms of health insurance plans, could also be at play, “I think the hidden secret here is it’s the consumer’s out-of-pocket costs that are increasing,” said Doug Hirsch, chief executive officer of drug price comparison GoodRx. Search data, as well as his own business, shows that consumers have reacted to the trend by shopping around, he said.

EpiPen became the most recent poster child for large drug price hikes, after its list price rose sixfold since Mylan acquired the device in 2007. But though Mylan is one of a handful of companies making the most significant price increases, it is hardly alone in its strategy — or even the player with the most egregious numbers.

Read more: Mylan’s EpiPen caught the full force of drug price outrage because it was the perfect target, not because it was the only one

Jazz Pharmaceuticals PLC’ JAZZ, +0.16% blockbuster narcolepsy drug Xyrem topped the list with a 248% price increase since 2011, according to a Sept. 9 biopharma analysis done by Leerink.

Mylan’s EpiPen came in second, at a 172% increase since 2011, followed by Sanofi ADR’s SNY, -1.94% Lantus’ 159% price increase, AbbVie Inc.’s ABBV, -0.55% Humira’s 100% price increase and Amgen Inc.’s AMGN, +1.77% Enbrel’s 100% price increase.

See: Allergan offers a rare pharmaceutical company promise: limits on drug-price increases

Pfizer Inc.’s PFE, +0.63% Lyrica and Viagra and Bristol-Myers Squibb Co.’s BMY, +1.71% Orencia were other “noteworthy” brands in this group, the report said.

Leerink’s analysis used list prices of 976 brands sold by over 50 biopharmaceutical companies between 2011 and 2016. Of the group, the median annual list price increase over that time period was about 10% a year, according to the report.

List prices are hardly the ideal measure of drug price increases, since significant discounts are typically negotiated or given, but they are the only publicly available number.